Vivalytic test for detecting SARS-CoV-2

April 1, 2020—Randox Laboratories and Bosch Healthcare Solutions will launch this month the Vivalytic Viral Respiratory Tract Infection Array, which can identify SARS-CoV-2 and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.

The Viral Respiratory Tract Infection Array is a multiplex molecular diagnostic test that runs on the Vivalytic point-of-care platform, brought to the market by Randox and Bosch. The test requires a single nasal swab from the patient.

The target gene for COVID-19 being used on the VRI array is ORF1ab and for Sarbecovirus it is the E gene.